MMP-9-IN-1

Cat. No.: HY-135232 Purity: 99.82%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs.

For research use only. We do not sell to patients.

CAS No. : 502887-71-0

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 8 publication(s) in Google Scholar

8 Publications Citing Use of MCE MMP-9-IN-1

Cell Proliferation/Viability Assay

In Vivo Efficacy Study

Cell Migration/Invasion Assay

Bio/Physico-chemical Assay

: MMP-9-IN-1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Dec 3;15(1):10536. [Abstract]; Transwell assays were employed to evaluate the migration and invasion abilities of Keap1-knockdown HCT116 cells treated with 40 μM MMP9 inhibitor MMP-9-IN-1 for 48 h (n = 5). The cells were harvested for western blotting analysis.

: MMP-9-IN-1 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Dec 3;15(1):10536. [Abstract]; Transwell assays were employed to evaluate the migration and invasion abilities of Keap1-knockdown HCT116 cells treated with 40 μM MMP9 inhibitor MMP-9-IN-1 for 48 h (n = 5). Representative images were captured. The scale bar was 200 μm.

: MMP-9-IN-1 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Feb 14;10(1):77. [Abstract]; Effect of MMP-9-IN-1 ( 0.1-10 µM; 24-72 h) on osteoblast proliferation.

: MMP-9-IN-1 purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 Feb 14;10(1):77. [Abstract]; MMP-9-IN-1 (0.1-10 µM; 72 h) significantly inhibited MMP-9 activity in cells.

: MMP-9-IN-1 purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2023 Sep 5:954:175858. [Abstract]; MMP-9-IN-1 (20 mg/kg; i.g.; once every other day for a total of 5 administrations) significantly increased mechanical allodynia to Von Frey filaments, prolonged the latency of thermal hyperalgesia, and reduced spontaneous pain behaviors in rats with bone cancer pain (BCP).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All MMP Isoform Specific Products:

View All Isoforms

MMP-1 MMP-2 MMP-3 MMP-8 MMP-9 MMP-13 MMP-14 MMP-17 ADAM10 ADAM17 MMP-7 MMP-12 MMP-10 MMP ADAM8 MMP-19

Biological Activity
Purity & Documentation
References
Customer Review

Description

MMP-9-IN-1 is a specific matrix metalloproteinase-9 (MMP-9) inhibitor, which selectively target the hemopexin (PEX) domain of MMP-9, but not other MMPs^[1].

IC₅₀ & Target^[1]

MMP-9

In Vitro

MMP-9-IN-1 (compound 2; 100 μM; 14 hours) does not cause notable cytotoxicity^[1].
MMP-9-IN-1 (compound 2; 10 μM) significantly inhibits cell proliferation of HT-1080 and MDA-MB-435 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[1]

Cell Line:	COS-1 monkey epithelial cell lines
Concentration:	100 μM
Incubation Time:	24 hours
Result:	Treatment did not cause notable cytotoxicity.

Cell Proliferation Assay^[1]

Cell Line:	HT-1080 and MDA-MB-435 cancer cells expressing endogenous MMP-9
Concentration:	10 μM
Incubation Time:	9 days
Result:	Significant inhibition of cell proliferation.

In Vivo

MMP-9-IN-1 (compound 2; 20 mg/kg; intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks) results in a profound delay in tumor growth in NCR-Nu mice bearing MDA-MB-435/GFP tumor^[1].
MMP-9-IN-1 inhibits cancer cell metastasis in vivo^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4-5 week-old female NCR-Nu mice bearing MDA-MB-435/GFP tumor^[1]
Dosage:	20 mg/kg
Administration:	Intraperitoneal and intratumoral injection alternately; 6 days/week; for 14 weeks,
Result:	Resulted in a profound delay in tumor growth. Inhibited cancer cell metastasis.

Molecular Weight

369.39

Formula

C₁₆H₁₇F₂N₃O₃S

CAS No.

502887-71-0

Appearance

Solid

Color

White to off-white

SMILES

O=C(NC1=CC=C(OC(F)F)C=C1)CSC2=NC(CCC)=CC(N2)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 66.67 mg/mL (180.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7072 mL	13.5358 mL	27.0717 mL
5 mM	0.5414 mL	2.7072 mL	5.4143 mL
10 mM	0.2707 mL	1.3536 mL	2.7072 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 50% PBS
Solubility: 5 mg/mL (13.54 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.63 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.82%

Select Batch:

Data Sheet (274 KB) SDS (393 KB)

COA (244 KB) HNMR (252 KB) LCMS (93 KB)

Handling Instructions (2659 KB)

References

[1]. Dufour A, et al. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9. Cancer Res. 2011 Jul 15;71(14):4977-88. [Content Brief]

[2]. Alford VM, Kamath A, Ren X, et al. Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions. ACS Chem Biol. 2017;12(11):2788-2803. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7072 mL	13.5358 mL	27.0717 mL	67.6791 mL
	5 mM	0.5414 mL	2.7072 mL	5.4143 mL	13.5358 mL
	10 mM	0.2707 mL	1.3536 mL	2.7072 mL	6.7679 mL
	15 mM	0.1805 mL	0.9024 mL	1.8048 mL	4.5119 mL
	20 mM	0.1354 mL	0.6768 mL	1.3536 mL	3.3840 mL
	25 mM	0.1083 mL	0.5414 mL	1.0829 mL	2.7072 mL
	30 mM	0.0902 mL	0.4512 mL	0.9024 mL	2.2560 mL
	40 mM	0.0677 mL	0.3384 mL	0.6768 mL	1.6920 mL
	50 mM	0.0541 mL	0.2707 mL	0.5414 mL	1.3536 mL
	60 mM	0.0451 mL	0.2256 mL	0.4512 mL	1.1280 mL
	80 mM	0.0338 mL	0.1692 mL	0.3384 mL	0.8460 mL
	100 mM	0.0271 mL	0.1354 mL	0.2707 mL	0.6768 mL

MMP-9-IN-1 Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MMP-9-IN-1502887-71-0MMPMatrix metalloproteinasesanti-metastaticcancerMDA-MB-435tumorlungmetastasishemopexinPEXMMP-9Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

MMP-9-IN-1

Customer Review

MMP-9-IN-1 Related Antibodies

8 Publications Citing Use of MCE MMP-9-IN-1

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All MMP Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

MMP-9-IN-1 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

MMP-9-IN-1 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report